KROS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KROS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Net margin is calculated as Net Income divided by its Revenue. Keros Therapeutics's Net Income for the three months ended in Dec. 2024 was $-46.03 Mil. Keros Therapeutics's Revenue for the three months ended in Dec. 2024 was $3.04 Mil. Therefore, Keros Therapeutics's net margin for the quarter that ended in Dec. 2024 was -1,513.02%.
The historical rank and industry rank for Keros Therapeutics's Net Margin % or its related term are showing as below:
The historical data trend for Keros Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Net Margin % | Get a 7-Day Free Trial | - | -292.26 | - | -101,319.21 | -5,277.55 |
Keros Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Net Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-28,141.96 | -51,944.58 | -122,316.22 | -13,648.45 | -1,513.02 |
For the Biotechnology subindustry, Keros Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's Net Margin % falls into.
Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.
Keros Therapeutics's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | -187.353 | / | 3.55 | |
= | -5,277.55 % |
Keros Therapeutics's Net Margin for the quarter that ended in Dec. 2024 is calculated as
Net Margin | = | Net Income (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | -46.026 | / | 3.042 | |
= | -1,513.02 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics (NAS:KROS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of Keros Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Carl L Gordon | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Keith Regnante | officer: Chief Financial Officer | 733 CONCORD AVENUE, CAMBRIDGE MA 02138 |
Alpna Seth | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Jennifer Lachey | officer: Chief Scientific Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Christopher Rovaldi | officer: Chief Operating Officer | C/O ACCELERON PHARMA INC., 128 SIDNEY ST., CAMBRIDGE MA 02139 |
Julius Knowles | director | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Simon Peter Cooper | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVE., BUILDING E, SUITE 120, LEXINGTON MA 02421 |
Claudia Ordonez | officer: Chief Medical Officer | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
Mary Ann Gray | director | 201 W 70TH ST, SUITE 23K, NEW YORK NY 10023 |
Pontifax Management 4 G.p. (2015) Ltd. | 10 percent owner | 14 SHENKAR STREET, BEIT OFEK, HERZLIYA PITUACH L3 46140 |
Ran Nussbaum | director, 10 percent owner | C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404 |
Tomer Kariv | director, 10 percent owner | C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822 |
Jasbir Seehra | director, officer: Chief Executive Officer | C/O ELOXX PHARMACEUTICALS, INC., 950 WINTER STREET, WALTHAM MA 02451 |
Alon Lazarus | director, 10 percent owner | C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON MA 02421 |
From GuruFocus
By Marketwired • 08-07-2024
By Marketwired • 08-28-2024
By Marketwired • 09-03-2024
By PRNewswire • 01-22-2025
By Marketwired • 12-10-2024
By Marketwired • 11-06-2024
By Marketwired • 01-15-2025
By Marketwired • 10-16-2024
By GuruFocus News • 02-15-2025
By Marketwired • 12-03-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.